Relypsa Adds Venture Funds In Another Effort To Reach Phase III
This article was originally published in The Pink Sheet Daily
Relypsa, spun out from Amgen in 2007, has raised a third round of financing in an effort to move its lead compound into late-stage development.
You may also be interested in...
After a bit of a lull since September, there are seven biotechnology IPOs slated to get out in the next few weeks. But they are entering a tougher market than earlier in 2013, and some may not be quite the same quality.
Plus news on recent financing activity by Novira Therapeutics, MediciNova, Elcelyx Therapeutics and Relypsa.
It was a good day for biotech venture news, as early-stage investor Third Rock closed its second fund and Relypsa reported a massive $70 million Series B funding to push its potassium binding agent into pivotal trials.